BMI of 30 or above, or BMI of 27 or above with an obesity-related health condition Health conditions such as high blood pressure, insulin resistance, sleep apnea, or elevated cholesterol History of unsuccessful attempts with diet, exercise, or commercial weight loss programs Willingness to combine medication with nutrition, movement, and lifestyle changes Not currently pregnant or planning pregnancy in the near term No contraindications to GLP-1 therapy based on health history and provider review Candidacy for compounded semaglutide and compounded tirzepatide is reviewed individually
Cant get away
Weight regain after stopping One thing to plan for is the likelihood of regaining some weight after stopping the medication
For instance, at three months, the average weight loss for Mounjaro was 5.9%, compared to Ozempic's 3.6%
Regulatory Compliance and International Certifications Shaanxi Hongda Phytochemistry maintains an extensive portfolio of international certifications that facilitate regulatory compliance in markets worldwide
Patients have seen up to a 20.9% reduction in body weight in clinical trials
